Clinical Trials Browser

Phase 2 × magrolimab × Other hematologic neoplasm × Clear all

NCT05829434 2024-02-12

MAGROLIC

Phase 2 Withdrawn

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute